Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner

Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

Pharmacy Benefit Update Fall/Winter 2019 Issue

Preferred Drug List (PDL) News

PDL Changes: This issue of the Pharmacy Benefit Updates contains information about changes to the Preferred Drug List for January 1, 2020, as well as updates on MaineCare pharmacy benefit changes.

Non-Preferred			
Acular Soln	Adcirca	Advair Diskus	Austedo
Azulfidine Tabs	Canasa Supp	Carbamazepine Er Cap	Carbamazepine Sus
Cimduo	Concerta Tbcr	Daytrana	Delzicol
Dexamethasone Drops	Elidel Crea	Eucrisa	Evotaz
Exforge Hct	Felbamate Sus	Flector Patch	Flurbiprofen Sodium Soln
Focalin Ir Tabs	Fycompa	Galantamine Hydrobromide Sol	Granix Syringe
Hemlibra	Humulin Inj 70/30	Levetiracetam Tabs	Lyrica Sol
Memantine Hcl Sol	Mesalamine Tab	Methylin Sol	Novolin 70/30 Pen
Orenitram	Oxcarbazepine Sus		Oxycodone Cap
Procrit Soln	Quetiapine Xr	Restasis Multidose Drops	Saphris Sublingual
Synjardy Xr	Tudorza	Viberzi	Vimpat
Vimpat Sol	Xenazine	Zepatier	

Preferred			
Afstyla	Amlodipine/Valsartan Hct	Aristada	Aristada Initio
Berinert Kit	Breo Ellipta	Brilinta	Chantix Starter Pack
Cinryze	Combivent Respimat	Complera	Dalfampridine Er
Delstrigo	Depo-Subq Provera 104	Dexmethylphenidate Ir Tabs	Fanapt
Firazyr	Gabapentin Cap	Gabapentin Tab	Gelnique Gel Md Pmp
Gelnique Gel Packet	Haegarda	Hemangeol Sol	Humalog 50/50 Vial
Humalog Mix 75/25	Humalog Mix Inj 75/25 Kwp	Humalog Mix Pen 50/50 Kwp	Humulin R Inj U-500
Humulin R U-500 Kwp	Ingrezza	Invega Sustenna	Invega Trinz Inj
Lamictal	Latuda	Levetiracetam Er Tabs	Levetiracetam Soln
Lotemax Drops Gel	Mesalamine Enema Kit	Methylphenidate Er Tabs (Generic Concerta labeler 10147)	Methylphenidate Sol
Methylphenidate Tab	Miconazole 3 Supp	Naproxen Dr Tbec	Naproxen Sodium Caps
Novolog Mix 70/30 Flexpen	Novolog Mix 70/30 Vial	Odefsey	Oxytrol
Pentasa	Perseris	Pimecrolinus Cream (Auth Generic labeler 00591)	Praluent (Labler 72733) Pen
Prednisolone Drops	Pregabalin (Oral) Sol	Retacrit	Risperdal Consta

Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner

Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

Rocklatan	Ruconest Vial	Spiriva Respimat	Tadalafil
Tegretol Sus	Tegretol Tab	Tetrabenazine	Tracleer
Tribenzor	Trulicity	Twynsta	Vandazole
Xtampza Er	Zyprexa Relprevv		
For a complete list of PDL changes and criteria, please go to www.mainecarepdl.com			

RSV Season

MaineCare has updated the Synagis prior authorization requirements for the upcoming RSV season. MaineCare will approve Synagis® PA requests for infants who meet the following guidelines. PA requests will be approved starting at the onset of RSV season for a maximum of 5 doses and a dosing interval not less than 30 days between injections. For MaineCare members, PA requests began November 8, 2019 for dates of service starting November 20, 2019. Synagis® were not to be authorized for administration prior to this date. Synagis® dosing authorizations will extend for the recommended number of doses or until the end of epidemic RSV season as defined by CDC - whichever occurs first. For a complete list of Synagis criteria please refer to the Synagis prior authorization form at www.mainecarepdl.org.

Naloxone Billing

MaineCare is currently working with Change Healthcare on an edit that would allow Pharmacist to prescribe naloxone as allowed by Title 22, Chapter 117, Section 2353, subsection 2, paragraph A-1 and C-1. The use of the pharmacist ***"dummy"*** DEA number (**RP2222222**) can be inputted in the claim submission as the prescriber DEA#. The use of this edit will allow pharmacies to bill in instances that naloxone is dispensed at the pharmacist discretion. This edit is similar to those allowed for DH - Dental Hygienist and OT – Optometrist. MaineCare is currently finishing its provider enrollment/validation project and once complete in early 2020, the pharmacy adjudication process in the pharmacy POS will be converted to prescriber NPI. We will notify pharmacies when this edit is fully implemented.

Utilization of 196 Override

MaineCare would like to remind pharmacies the about the appropriate use of the 196 override. Pharmacies can utilize the 196 override to fill a 4 day (96 hour) emergency supply, but this override should only be used outside of normal Help Desk Hours. An example of the 196 could be used to fill an emergency 4-day supply of Buprenorphine Mono for a pregnant MaineCare member. In this case both a diagnosis of pregnancy and opiate/substance abuse are required to be written/printed on the prescription.

Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner

Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

Prior Authorization (PA) Statistics October 2019

Top Five Drugs by PA	
DRUG	**CLAIM COUNT**
AMPHETAMINE/DEXTROAMPHETAMINE	325
OXYCODONE HCL	278
HYDROCODONE/ACETAMINOPHEN	232
MELATONIN	203
LATUDA	174
Top Five Specialty Drugs by PA	
DRUG	**CLAIM COUNT**
MAVYRET	87
NEXPLANON	35
AIMOVIG	29
HUMIRA PEN	24
EPCLUSA	19

FDA Alerts

FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib)
https://www.fda.gov/Drugs/DrugSafety/ucm626923.htm?utm_campaign=New%20FDA%20Drug%20Safety%20Communication%20on%20Idhifa%20%28enasidenib%20mesylate%29-%20Drug%20I&utm_medium=email&utm_source=Eloqua

Fluoroquinolone Antibiotics: Safety Communication - Increased Risk of Ruptures or Tears in the Aorta Blood Vessel in Certain Patients
https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm628960.htm?utm_campaign=FDA%20MedWatch%20-%20Fluoroquinolone%20Antibiotics&utm_medium=email&utm_source=Eloqua

FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab)
https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm?utm_campaign=FDA%20MedWatch%20-%20Lemtrada%20%28alemtuzumab%29%3A%20Drug%20Safety%20Communication&utm_medium=email&utm_source=Eloqua

The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. Mavyret was previously approved to treat HCV in adults in 2017.

Janet T. Mills
Governor

Jeanne M. Lambrew, Ph.D.
Commissioner

Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

http://s2027422842.t.en25.com/e/es?s=2027422842&e=210380&elqTrackId=78D8A052C380BCBFF284D754BEBE9730&elq=380e0dc31c3f4cd2b39485cf0d6eb7b6&elqaid=7835&elqat=1

FDA Hepatitis Update: VIREAD Pregnancy Label Updates
http://s2027422842.t.en25.com/e/es?s=2027422842&e=208411&elqTrackId=78D8A052C380BCBFF284D754BEBE9730&elq=ce5ca0323e0f457cba72a3050f17ff99&elqaid=7752&elqat=1

FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)
https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and

FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease
https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrence-serious-liver-injury-use-hepatitis-c-medicines-mavyret-zepatier-and?utm_campaign=Hep%20C%20DSC%20liver%20injury&utm_medium=email&utm_source=Eloqua

Drug Utilization Review (DUR) Committee Meetings

Comments on the PDL or any PAs, either proposed or already in effect, may be made at these meetings or by e-mail, letter, or phone if more convenient.

Date: March 10, 2020
Time: 5:30-8:30pm
Location: The Armory, Augusta (Augusta, ME)

For DUR questions, you may contact:
Jill Kingsbury, Director of Pharmacy, MaineCare Services
Jill.Kingsbury@maine.gov

For PA/PDL questions, you may contact:
Michael Ouellette, R.Ph mouellette@changehealthcare.com
Jeffrey Barkin, MD jbarkin@changehealthcare.com

Pharmacy Help Desk Hours:
Monday- Friday 8am- 5pm

For emergencies the Pharmacy Help Desk:
Monday- Friday 5pm-8pm
Saturday 8am- 8pm
Sunday 8am- 8pm

Please leave a message on the urgent voicemail and your call will be returned 15 minutes all non-urgent voicemails will be returned the next business day.